{
    "id": 11085,
    "fullName": "MPRIP - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MPRIP-NTRK1 results from the fusion of MPRIP and NTRK1, leading to constitutive kinase activity of Ntrk1 and tumor formation in xenograft models (PMID: 24162815).",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 23164,
        "geneSymbol": "MPRIP",
        "terms": [
            "MPRIP",
            "M-RIP",
            "MRIP",
            "p116Rip",
            "RHOIP3",
            "RIP3"
        ]
    },
    "variant": "MPRIP - NTRK1",
    "createDate": "08/31/2015",
    "updateDate": "11/28/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9720,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lestaurtinib (CEP-701) inhibited NTRK1 phosphorylation and decreased proliferation of a lung adenocarcinoma cell line harboring MPRIP-NTRK1 in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16264,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH7057288 inhibited NTRK phosphorylation and downstream signaling and reduced growth of non-small cell lung cancer cells harboring MPRIP-NTRK1 in culture, induced tumor regression in subcutaneous xenograft models, and induced tumor regression and prolonged event-free survival in intracranial xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3062,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) treatment resulted in some clinical activity in a lung adenocarcinoma patient harboring the MPRIP-NTRK1 fusion, demonstrating decreased tumor size and reduced CA125 serum levels (PMID: 24162815).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3019,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling of transformed cells expressing MPRIP-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9721,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-536924 inhibited NTRK1 phosphorylation and decreased proliferation of a lung adenocarcinoma cell line harboring MPRIP-NTRK1 in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 683,
                "therapyName": "BMS-536924",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3017,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling of transformed cells expressing MPRIP-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3244,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth and downstream signaling in human lung adenocarcinoma cells harboring MPRIP-NTRK1 in culture (PMID: 26216294).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3689,
                    "pubMedId": 26216294,
                    "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26216294"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3018,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lestaurtinib (CEP-701) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling of transformed cells expressing MPRIP-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11129,
                "profileName": "MPRIP - NTRK1"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16267,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH7057288 inhibited growth of cells expressing MPRIP-NTRK1 harboring NTRK1 G667C in culture, and induced tumor regression in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 31577,
                "profileName": "MPRIP - NTRK1 NTRK1 G667C"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16270,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MPRIP-NTRK1 harboring NTRK1 G595R demonstrated resistance to growth inhibition by Rozlytrek (entrectinib) in culture and in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 31578,
                "profileName": "MPRIP - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MPRIP-NTRK1 harboring NTRK1 G595R demonstrated resistance to growth inhibition by Vitrakvi (larotrectinib) in culture and in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 31578,
                "profileName": "MPRIP - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MPRIP-NTRK1 harboring NTRK1 G595R demonstrated resistance to growth inhibition by CH7057288 in culture and in xenograft models (PMID: 30242093).",
            "molecularProfile": {
                "id": 31578,
                "profileName": "MPRIP - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 7977,
                "therapyName": "CH7057288",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14399,
                    "pubMedId": 30242093,
                    "title": "Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30242093"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11129,
            "profileName": "MPRIP - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 6443,
                    "name": "TrkA Receptor Inhibitor",
                    "profileName": "MPRIP - NTRK1"
                },
                {
                    "id": 19343,
                    "name": "Larotrectinib",
                    "profileName": "MPRIP - NTRK1"
                },
                {
                    "id": 6444,
                    "name": "Crizotinib",
                    "profileName": "MPRIP - NTRK1"
                },
                {
                    "id": 6442,
                    "name": "Trk Receptor Inhibitor (Pan)",
                    "profileName": "MPRIP - NTRK1"
                }
            ]
        },
        {
            "id": 30948,
            "profileName": "MPRIP - NTRK1 NTRK1 V573M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31577,
            "profileName": "MPRIP - NTRK1 NTRK1 G667C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31578,
            "profileName": "MPRIP - NTRK1 NTRK1 G595R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}